Matthew Campell, professor in Genetics at Trinity said in a report by a report by Science Advances: “This exciting project allowed us to bridge the gap between academia and industry and work very closely with a gene therapy company to develop a cutting-edge therapy that we believe holds immense promise for patients in the future.”